Statin treatment significantly reduced the incidence of atherosclerotic CVD by 24% and all cause mortality by 16% in participants aged 75-84 years with type 2 diabetes.
Cohort (n=46,864)
No
Does statin treatment reduce atherosclerotic CVD and mortality in adults aged 75 years or older with and without type 2 diabetes?
Statins for primary prevention in adults ≥75 years old do not reduce ASCVD or mortality in those without diabetes, but provide significant protective benefits in those with type 2 diabetes up to age 85.
Effect estimate: HR 0.76 (95% CI 0.65 to 0.89)
In participants older than 74 years without type 2 diabetes, statin treatment was not associated with a reduction in atherosclerotic CVD or in all cause mortality, even when the incidence of atherosclerotic CVD was statistically significantly higher than the risk thresholds proposed for statin use. In the presence of diabetes, statin use was statistically significantly associated with reductions in the incidence of atherosclerotic CVD and in all cause mortality. This effect decreased after age 85 years and disappeared in nonagenarians.
Ramos et al. (Wed,) conducted a cohort in atherosclerotic cardiovascular disease (n=46,864). statins vs. placebo was evaluated on atherosclerotic CVD and all cause mortality (HR 0.76, 95% CI 0.65 to 0.89). Statin treatment significantly reduced the incidence of atherosclerotic CVD by 24% and all cause mortality by 16% in participants aged 75-84 years with type 2 diabetes.